Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Enzon Pharmaceuticals, Inc. announced that it has opened its first Phase II trial for PEG-SN38, its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer.


Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address